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Abstract
Polymers and self aggregating molecules have been widely tested as vaccine adjuvants. For this type of adjuvant, 
electrostatic potential can be managed through the selection of chemical synthesis routes and monomer types in order 
to control adsorption phenomena of amphiphilic charged macromolecules according to isoelectric points at different 
pH. Thanks to an original polymerisation process, compatible with injectable polymers development, calibrated 
spheric micronic gel particles of sodium polyacrylate have been synthesised. These aggregates measuring about one 
micrometer in diameter are made of a reticulated high molecular weight synthetic polymer. Adsorption properties 
(possibly leading to sustained release) persistence at the injection site and irritation phenomena are the main 
mechanism of action identified as responsible for immune response improvement. Synthetic cross 
linked macromolecules, highly chemically stable and used at low rate can persist at injection site. Microgel particles 
have been characterised with one model antigen to establish binding constants in various conditions. During 
development steps, safety profile of this innovative formula was assessed through Guinea pig histological studies after 
intramuscular injection and compared to aluminium salts based adjuvant. 
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1. Introduction 
Adjuvants technologies dedicated to veterinary vaccines are mainly aluminium salts and oil based 
vaccines [Audibert and Lise, 1993; Cox and Coulter , 1997]. Oil based vaccines are well known as 
powerful adjuvant and are used in the field when a strong immune response is needed [Aucouturier et al,
2001]. Aluminium salts are sometimes considered as a reference in term of safety and are used in most of 
the more sensitive species because of their safety profile [Oda K et al 2006]. Nevertheless those two kinds 
of adjuvants are presenting drawbacks either in their safety profile [Oda K et al 2006] or ability to induce 
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an efficacious immune response [Aucouturier et al, 2001]. Many physiochemical parameters and 
biological properties have been optimised to create a new adjuvant based on a dispersion of a high 
molecular weight polyacrylic polymer. This new adjuvant is a dispersion of highly stable calibrated 
spheric micronic gel particles of sodium polyacrylate in water. Montanide™ Gel 01 has already been used 
in several vaccine models with a promising safety and efficacy profile [Parker et al 2008]. Nevertheless, 
sparse data can be found upon physico-chemical characterisation and very few is known upon mechanism 
of action. In this study, we investigated the Montanide™ Gel 01 physical characteristic and properties 
linked to the adjuvant mechanism of action: particle sizing and ability to fix antigenic proteins have been 
studied. Expected mechanisms of action are three: a depot effect, an arrangement of the antigen in a 
particulate form around the polymer and pro-inflammatory properties. Therefore, inflammatory profile of 
the Montanide™ Gel 01 has been illustrated in a laboratory animal model and microgel particles, globally 
negatively charged, have been characterised for their ability to adsorb antigens. An ovalbumine adsorbing 
model was studied in vitro by antigen specific ELISA methods.  
2. Material and methods 
2.1. Microgel particle aspect and size distribution 
Polymer aspect was characterised by two distinct criteria: direct observation of Gel dispersion and 
particle sizing. Polymer particles were prepared by organic solvent washings followed by 3 hours drying. 
A suspension of the extracted polymer was then prepared in a solution of NaCl 2%. The collected particles 
were observed under white light microscope with 600 magnification rate.  
Microparticle sizing was performed on a polymer suspension prepared as described for the direct 
microscopic observation. Polymer particle sizing was performed using a Malvern Mastersizer S equipped 
with a small volume sample dispersion unit. The dispersion is diluted in water and passed in a capillary 
system equipped with laser light and diffraction detectors. The size and volume of the particle is calculated 
according to the light diffraction and expressed in micrometers.
2.2. Antigen adsorption 
Quantification of adsorption of a model antigen Albumin from chicken egg white (ref A55O3-5G, 
SIGMA) (OVA) onto Montanide GEL particles have been performed by ELISA. Constant concentration 
of OVA (100µg/ml) was blend with different concentrations of Montanide GEL 01 ranging from 0 to 5%, 
and left overnight at 4°C. ELISA method was used to detect and quantify the free protein in the antigenic 
phase after the gel adsorption activity. Montanide™ Gel 01 plus OVA mix was added in ELISA plate 
(Nunc Maxisorp, ref 055133) and incubated at 37°C for 2 hours. The plates were then washed with PBS / 
Montanox™ 20 (Polysorbate20, SEPPIC) 0.05%. After three washings, the plates were incubated with 
200µl of blocking solution (5% swine gelatin, Prolabo), 0.05% Montanox™ 20 in PBS) for 30 min at 
37°C. A mouse serum containing an IgG1 antibody high titre and diluted 1/1000 in blocking solution was 
added (100µl). Plates were incubated for 1h at 37°C and washed 3 times. Goat anti - mouse IgG1 HRPO 
(Invitrogen ref M32007), diluted 1/6000 in blocking solution was added (100µl) and the plates were 
incubated for 1h at 37°C. The peroxidase activity was visualized with TMB (100µl) (ZYMED), stopped 
with 50µl of H2SO4 (12.5%). The optical density (OD) is evaluated at 450nm. OD quantifies the amount of 
OVA in solution and not linked to polymer particles. 
2.3. Safety study in laboratory animal model. 
Safety profile of Montanide™ Gel 01 was defined in a guinea pig model. Placebo formulation was used 
to define the intrinsic inflammatory properties of the adjuvant without any potential synergic effect of an 
antigen. For this study, placebo formulations studied were containing either 10% of Montanide™ Gel 01 
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or 1% of Aluminium hydroxide (Superfoss). Placebo vaccines were injected intramuscularly at day 0 and 
28 in the hind leg under 100µl volume. The injected muscle was sampled after at day 14, 56 and 90 for 
histological study of the vaccine born reactions in the injection site. All biopsy were analyzed through 
Hemalun Eosin Safran coloration (HES), this work was performed by IDEXX Alfort laboratories 
(Alfortville, France). This specific coloration of samples allows the identification in the injection site of all 
cell population present as well as necrosis, fibrosis and vaccine remnants. 
3. Results 
3.1. Microgel particle aspect and size distribution 
Optical observation of particles gives a semi-quantitative assessment of homogeneity (fig 1).  
Fig 1: microscopic observation of Montanide GEL  
01 micropacticles. 
Figure 2 presents the particle size repartition observed in water: 50% (in volume) of the particles are 
smaller than 0.5 µm and 90% of the particles are smaller than 1.2 µm in diameter. 
Fig 2: particle size distribution of microgel particles in water 
measure by laser light diffraction.  
3.2. Antigen adsorption 
A constant amount of 100µg of antigens induces decreasing OD according to a range of Montanide™ 
Gel concentration from 0 to 5%. The blank without adjuvant in the mix give an OD measured at 1.6; 0,5% 
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of adjuvant in the mix give a decrease of 50% of OD. The addition of 5% of Montanide™ Gel in the mix 
reduces the OD to the negative control level. Results indicate an immediate quenching of OD 
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Fig 3: OD detected by ELISA after fixing 100µg of OVA on Montanide™ Gel 01 from 0 to 5%.  
3.3. Safety study in laboratory animal model 
Figure 4 presents the Hemalun Eosin Safran coloration results of the injection site observed in the 
guinea pig muscles. All pictures present at short term after injection an intense reaction in the injected 
muscle: strong inflammation with large infiltration of muscle by immune cells and even necrosis for the 
aluminium salts based adjuvant. These salts are inducing such intense reaction even at long term after 
injection: 90 days after first injection (meaning 62 days after booster) some granulomatous injection and 
adjuvant remnants are still found in the injection site. The Montanide™ Gel 01 based vaccines is 
presenting a different profile as no reactions could be observed in the muscle sampled at day 56 or 90. 
Fig 4: Local reactions observed in subcutaneous tissue biopsies performed in guinea pigs 14, 56 and 90 days after first injection of 
several vaccines. a: normal tissue, b: granulomas, c: necrotic tissues, d: fibrosis, e: vaccine remnants. 
4. Discussion 
Direct observation of the polymer particles indicates homogeneous small individual particles. These 
polymeric individual particles have been characterised as having a smaller diameter than 1.2µm for 90% of 
the volume they occupy in the solution. This particle size, close to 1µm, is optimum for an efficacious 
phagocytosis [Lindblad 2004]. ELISA protocol used to characterize adjuvant/antigen interaction is still 
studied: on going test will validate that the presence of the adjuvant is not leading to unspecific 
perturbation of ELISA coating step. Nevertheless, the optical density measured by OVA specific ELISA 
demonstrated that in presence of Montanide™ Gel 01 the antigen is no longer able to coat the plastic walls 
of the ELISA plate wells. In the meantime, Montanide™ Gel 01 has been demonstrated to induce a short 
term strong inflammatory response needed to trigger an efficacious immune response: as observed 14 days 
after injection, a strong infiltration of monocytes and macrophages is induced by injection of Montanide™ 
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Gel based placebo in muscle tissues. Compared to aluminium salts adjuvant formulation, the inflammatory 
process is shorter avoiding chronic inflammatory response that can be responsible for vaccine born side 
effects [Day et al, 2007]. One of the Montanide™ Gel 01 mechanisms of action of adjuvant is therefore 
linked to its safety profile. Indeed, the inflammatory response observed at short term after injection of 
vaccine based on Montanide™ Gel 01 insures the recruitment in the injected area of monocytes and 
macrophages: phagocyting cells of the innate immune systems. At last, we demonstrated that the polymer 
from Montanide™ Gel 01 presents a strong ability to fix antigenic proteins probably to its surface. 
Therefore, we can assume that Montanide™ Gel 01 based vaccine injection will induce the immune 
response against an antigen through three main ways: 
x Antigen sustained release the injection site.  
x Recruitment of the innate immune system by a pro-inflammatory profile in the injected muscle. 
x Enhanced phagocytosis of the antigen complex with the polymer therefore raising the activity of 
antigen presenting cells.
Innate immune system will then trigger the adaptive immune system to build a highly specific immune 
response. At last, these results are consistent with data collected in other animal models such as dog and 
pigs [Deville et al, 2008; Dupuis et al, 2008; Parker et al 2008]. 
5. Conclusion 
Few mechanisms of action of adjuvant technologies are described in the literature. Polymers have been 
widely tested and sometimes used as vaccine adjuvants. This work is presenting data upon the mode of 
action of one specific sodium polyacrylate based polymer adjuvant linking chemical interaction of antigen 
and adjuvant to the inflammatory process attracting the immune cells in the injected area. Control of 
synthesis parameters such as microgel particle size and surfacial electrostatic charge added possibility to 
design easily adjuvants for specific antigens. 
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